PMHS Polomar Health Services, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1265521 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11,701.9%
TTM net income YoY-303.9%
TTM EPS YoY-300.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin49.1%
Operating margin-221.0%
Net margin-224.6%
FCF margin—
EBITDA margin-14.8%
Returns
ROE-469.6%
ROA-193.3%
ROIC (approx.)-392.6%
Asset turnover0.86x
Leverage & solvency
Liabilities / assets325.5%
Debt / equity—
Current ratio0.24x
Interest coverage-61.19x
Cash quality & payout
Operating cash flow / net income-0.04x
Accruals ratio-200.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.13M | $1.55M | $1.06M | $632,057 | $6,163 | $5,470 | $4,542 | $20,870 |
| Cost of revenue | $619,340 | $715,409 | $707,163 | $183,294 | $1,840 | $1,638 | $1,360 | $11,800 |
| Gross profit | $514,435 | $833,873 | $349,724 | $448,763 | $4,323 | $3,832 | $3,182 | $9,070 |
| SG&A expense | $474,367 | $125,165 | $144,901 | $9.36M | $619,032 | $556,658 | $398,836 | $702,282 |
| Operating income | -$467,876 | $141,701 | -$391,163 | -$8.94M | -$628,808 | -$563,333 | -$415,408 | -$689,112 |
| Interest expense | $45,674 | $38,225 | $27,765 | $46,198 | $20,967 | $42,230 | $41,447 | $29,677 |
| Net income | -$513,550 | $103,476 | -$418,928 | -$8.99M | -$649,775 | -$605,563 | -$456,855 | -$718,790 |
| EBITDA | -$468,275 | $151,189 | -$381,675 | $53,276 | -$369,696 | -$304,220 | -$156,295 | -$433,162 |
| EPS (basic) | -0.02 | 0.00 | -0.01 | — | -0.02 | -0.02 | -0.02 | — |
| EPS (diluted) | -0.02 | 0.00 | -0.01 | — | -0.02 | -0.02 | -0.02 | — |
| Weighted avg. shares (diluted) | 28.38M | 28.06M | 28.02M | — | 28.01M | 27.67M | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $254,779 | $178,872 | $87,818 | $132,150 | $38,854 | $4,678 | $129,331 | $6,191 |
| Inventory | $8,536 | $30,119 | $208,981 | $93,636 | $158,810 | $74,395 | $70,024 | $68,777 |
| Current assets | $673,560 | $2.36M | $2.21M | $322,727 | $197,664 | $93,054 | $201,200 | $76,813 |
| PP&E, net | $24,875 | $24,476 | $33,964 | $43,452 | $52,941 | $62,429 | $71,917 | $81,405 |
| Total assets | $886,874 | $817,739 | $567,968 | $390,043 | $9.27M | $9.43M | $9.81M | $9.95M |
| Current liabilities | $2.79M | — | $1.76M | $1.61M | $1.50M | $1.04M | $1.66M | $1.34M |
| Total liabilities | $2.89M | $1.87M | $1.76M | $1.61M | $1.50M | $1.04M | $1.67M | $1.35M |
| Shareholders' equity | -$2.84M | -$2.35M | -$2.39M | -$1.97M | $7.02M | $7.65M | $8.14M | $8.60M |
| Shares outstanding | 28.38M | 28.28M | 28.05M | 28.02M | 28.02M | 27.95M | 27.66M | 27.66M |
| Cash flow statement | ||||||||
| Operating cash flow | $38,314 | $121,306 | $34,376 | $190,021 | -$352,659 | -$187,780 | -$45,577 | -$314,995 |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$314,995 |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $37,593 | -$30,252 | -$78,708 | -$96,725 | $386,835 | $63,127 | $168,717 | $304,984 |
| Depreciation & amortization | -$399 | $9,488 | $9,488 | $9.00M | $259,112 | $259,113 | $259,113 | $255,950 |
| Stock-based compensation | — | — | — | -$12 | $20,426 | — | — | — |
| Dividends paid | $7,670 | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.